Thalidomide

Treatment approaches for ASCT-eligible myeloma patients in the frontline 3:01
Treatment approaches for ASCT-eligible myeloma patients in the frontline
Mohamad Mohty
New developments in maintenance therapy for multiple myeloma 5:11
New developments in maintenance therapy for multiple myeloma
Graham Jackson
The evolving role of IMiDs 5:36
The evolving role of IMiDs
Xavier Leleu
The impact of CHIP expression on multiple myeloma treatment 3:24
The impact of CHIP expression on multiple myeloma treatment
Irene Ghobrial
PET/CT in multiple myeloma monitoring 2:14
PET/CT in multiple myeloma monitoring
Aurore Perrot
CASSIOPEIA: D-VTD in high-risk multiple myeloma 2:51
CASSIOPEIA: D-VTD in high-risk multiple myeloma
Aurore Perrot
Induction and front-line therapy for myeloma 3:59
Induction and front-line therapy for myeloma
Maria-Victoria Mateos
Retrospective analysis of lenalidomide and thalidomide in myelofibrosis 3:21
Retrospective analysis of lenalidomide and thalidomide in myelofibrosis
Andrew Kuykendall
Future JAK inhibitor combination approaches in myelofibrosis 3:51
Future JAK inhibitor combination approaches in myelofibrosis
Andrew Kuykendall
Managing myeloma during COVID-19: German perspective 4:41
Managing myeloma during COVID-19: German perspective
Katja Weisel
TOURMALINE-AL1: ixazomib for AL amyloidosis 3:36
TOURMALINE-AL1: ixazomib for AL amyloidosis
Angela Dispenzieri
Immunomodulation for improving long-term outcomes in myeloma 5:18
Immunomodulation for improving long-term outcomes in myeloma
Michel Delforge
AGMT_MM-1: the oral microbiome as a predictor of PFS in R/R myeloma 4:23
AGMT_MM-1: the oral microbiome as a predictor of PFS in R/R myeloma
Heinz Ludwig
KRd vs KTd followed by K maintenance or control for high-risk myeloma 3:24
KRd vs KTd followed by K maintenance or control for high-risk myeloma
Heinz Ludwig
Positive learnings in myeloma management to come out of COVID-19 pandemic 4:00
Positive learnings in myeloma management to come out of COVID-19 pandemic
Mohamad Mohty
Update on auto-SCT for myeloma 4:36
Update on auto-SCT for myeloma
Mohamad Mohty
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals